958297-39-7

Basic information

• Product Name: 3-hydroxy-3-phenylazetidine trifluoroacetate
• Synonyms: 3-hydroxy-3-phenylazetidine trifluoroacetate
• CAS NO: 958297-39-7
• Molecular Formula: C₂HF₃O₂*C₉H₁₁NO
• Molecular Weight: 245.1978096
• EINECS: -0
• Mol File: 958297-39-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-hydroxy-3-phenylazetidine trifluoroacetate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hydroxy-3-phenylazetidine trifluoroacetate(958297-39-7)
• EPA Substance Registry System: 3-hydroxy-3-phenylazetidine trifluoroacetate(958297-39-7)

Safety Data

• Hazardous Substances Data: 958297-39-7(Hazardous Substances Data)

Upstream product

• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 76-05-1 trifluoroacetic acid 
• 100-58-3 phenylmagnesium bromide 
• 398489-25-3 tert-butyl 3-hydroxy-3-phenylazetidine-1-carboxylate 

Downstream Products

• 1225439-24-6 N-[(S)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)-1-(4-methoxybenzyl)-2-oxoethyl]-3-(1H-imidazol-4-yl)propionamide trifluoroacetate 
• 1451993-04-6 (5-amino-3,4-dimethylthieno[2,3-c]pyridazin-6-yl)(3-hydroxy-3-phenylazetidin-1-yl)methanone 

Relevant articles and documents

SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4

In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6- carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.